Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Age
18–75
Sex
FEMALE
Healthy volunteers
Not accepted
You may be eligible if
ECOG score 0-1
ER\>10%, PR\>10%, HER2(0)/HER2(1+)/HER2(2+) and no amplification of FISH
BRCA1/2 gene mutation
No other site metastases were detected by imaging evaluation after surgical treatment
Non-PCR breast cancer after neoadjuvant therapy, or breast cancer with postoperative pathology indicating ≥pN2
The patient had no major organ dysfunction
You may not be if
Allergic to the investigational drug, inability to take the drug orally, or refusal of the medication regimen
Has been enrolled in another study or has been discontinued for less than or equal to 4 weeks
There is serious dysfunction of vital organs (heart, liver, kidney)
Patients with other malignancies, except cured non-melanoma skin cancer, cervical carcinoma in situ and other tumors that have been cured for at least 5 years
In other acute infectious disease or chronic infectious disease activity period
A history of uncontrolled seizures, central nervous system disorders, or mental disorders
There is a known history of human immunodeficiency virus
Clareo Health | A Multicenter Prospective Cohort Study of Adjuvant Therapy for BRCA1/2 Mutated Hormone Receptor-positive HER2-negative Early High-risk Breast Cancer
